Patents
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
02/2011
02/09/2011EP1280898B1 Modified es cells and es cell-specific gene
02/09/2011EP0848755B2 Vegf-related protein
02/09/2011EP0668777B2 Prostate-specific membrane antigen
02/09/2011CN1859926B Polymer encapsulation of adenoviruses
02/09/2011CN101970645A Method for producing vaccinal viral strain of a virus of the reoviridae family
02/09/2011CN101970013A Novel therapeutical tools and methods for treating blindness
02/09/2011CN101967495A Construction of C35 gene siRNA expression vector of breast cancer cell and antineoplastic therapy application
02/09/2011CN101967187A Protein related to cell stress, and coding gene and application thereof
02/09/2011CN101967186A Encephalitis virus protein and code gene and application thereof
02/09/2011CN101967185A Encephalitis virus protein as well as coding gene and application thereof
02/09/2011CN101966341A Adenovirus/viruses A replicon chimeric vector hogcholeravaccine and application thereof
02/09/2011CN101966337A Genetic products differentially expressed in tumors and the use thereof
02/09/2011CN101966336A Recombinant attenuated salmonella typhimurium vector vaccine for expressing CSFV (Classical Swine Fever Virus) immunogenic gene and preparation method thereof
02/09/2011CN101966332A Application of gap junction protein and coding gene thereof in preparing medicament for reversing malignant phenotype of cancer stem cell
02/09/2011CN101020044B Regulating and controlling effect of thymine DNA glycosylase on signal transducing path
02/08/2011US7884179 monoclonal antibodies or antigen binding fragments that specifically to six transmembrane epithelial antigens of the prostate (STEAP-1), used for medical diagnosis, prognosis, prophylaxis and/or therapy for cancers
02/08/2011US7884084 Oligonucleotide seqences for controlling expression of leptin receptor gene associated protein (OB-RGRP); for treatment and prevention of bone, thrombic, sexual, blood, immunological, inflammatory and cancer disorders
02/08/2011US7884082 Combined therapeutical treatment of hyperproliferative diseases
02/08/2011US7883896 for early diagnosis, prognosis and monitoring of the disease course and for therapy and vaccination of cell proliferative disorders such as lung adenocarcinoma, lung carcinoma
02/08/2011US7883889 Using 5-aza-cytidine or 5-aza-2'-deoxycytidine to hypomethylate cells expressing tumor associated antigens; immunotherapy; genetic vaccines and the diagnosis, prevention and treatment of cancer
02/08/2011US7883880 DNA polymerase lambda and uses thereof
02/08/2011US7883868 Nucleotide sequences coding beta -10 glycoprotein hormone use in diagnosis and prevention of thyroid gland disorders
02/08/2011US7883720 Charge-dynamic polymers and delivery of anionic compounds
02/08/2011US7883696 deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells; Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene
02/08/2011US7883688 Polycationic polyrotaxanes capable of forming complexes with nucleic acids
02/08/2011CA2320419C Compositions comprising viruses and methods for concentrating virus preparations
02/08/2011CA2295971C Pseudomonas exotoxin a-like chimeric immunogens
02/08/2011CA2273825C Cytopathic viruses for therapy and prophylaxis of neoplasia
02/08/2011CA2217967C Augmentation in serca2 mediated calcium ion transport for regulation of cardiac muscle contractility
02/08/2011CA2210467C Osteoprotegerin
02/08/2011CA2164226C Methods for selectively stimulating proliferation of t cells
02/03/2011WO2011014388A1 Adipose-derived stromal cells (asc) as delivery tool for treatment of cancer
02/03/2011WO2011013700A1 Carrier peptide fragment and use thereof
02/03/2011WO2011013699A1 Carrier peptide fragment and use thereof
02/03/2011WO2011013698A1 Carrier peptide fragment and use thereof
02/03/2011WO2011012724A1 Widespread gene delivery to the retina using systemic administration of aav vectors
02/03/2011WO2011012716A1 Oligonucleotides inhibiting cellular migration
02/03/2011WO2011012707A1 PRODUCTION OF β-CELLS
02/03/2011WO2011011927A1 Use of rnf13 protein and encoding gene thereof in the preparation of medicaments for preventing and/or treating mental cognitive disorders
02/03/2011WO2010053597A3 Micelles of hydrophilically shielded membrane-destabilizing copolymers
02/03/2011WO2007035872A3 Tdf-related compounds and analogs thereof
02/03/2011US20110028691 Recombinant toxin fragments
02/03/2011US20110028690 Novel bag proteins and nucleic acid molecules encoding them
02/03/2011US20110028537 Somatic cell reprogramming
02/03/2011US20110028535 Oligonucleotides-transferring preparations
02/03/2011US20110027883 Rna interference mediating small rna molecules
02/03/2011US20110027879 Adipose-derived stem cells and lattices
02/03/2011US20110027319 Methods of eliciting or boosting a cellular immune response
02/03/2011US20110027318 Nucleotide vector, composition containing such vector, and vaccine for immunization against hepatitis
02/03/2011US20110027306 TC-83-Derived Alphavirus Vectors, Particles and Methods
02/03/2011US20110027279 Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
02/03/2011US20110027241 Intraperitoneal Delivery of Genetically Engineered Mesenchymal Stem Cells
02/03/2011US20110027240 Secretable hiv entry inhibitory peptides for therapy of hiv infection
02/03/2011US20110027237 Intraperitoneal Delivery of Genetically Engineered Mesenchymal Stem Cells
02/03/2011US20110027231 Method for the random diversification of a genetic sequence while preserving the identity of some inner segments of said genetic sequence
02/03/2011CA2769745A1 Widespread gene delivery to the retina using systemic administration of aav vectors
02/03/2011CA2769538A1 Oligonucleotides inhibiting cellular migration
02/02/2011EP2280082A2 Identification of surface-associated antigenes used for the diagnosis and therapy of tumours
02/02/2011EP2280074A2 Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
02/02/2011EP2280070A1 Methods and compositions for RNAi mediated inhibition of gene expression in mammals
02/02/2011EP2280066A2 Recombinant Clostridium neurotoxin fragments
02/02/2011EP2280030A2 Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
02/02/2011EP2280019A1 Antisense modulation of C-reactive protein expression
02/02/2011EP2279253A2 Engineering and delivery of therapeutic compositions of freshly isolated cells
02/02/2011EP1875247B1 Selective modulation of tumour necrosis factor receptors in therapy
02/02/2011CN1844387B Antisense oligonucleotide structure inhibiting Sirt1 gene expression and use thereof
02/02/2011CN101965196A Sugar chain-related gene and use thereof
02/02/2011CN101962648A Duck source coronavirus ORF1a protein gene and cloning method and application thereof
02/02/2011CN101962642A Interference RNA for targeting CCP22 gene, medicament composition containing interference RNA and application thereof
02/02/2011CN101962413A Fusion protein with transdermal capability and interleukin-10 activity as well as coding gene and application thereof
02/02/2011CN101961497A Inhibition of Syk kinase expression
02/02/2011CN101961493A Ace2 activation for treatment of heart, lung and kidney disease and hypertension
02/02/2011CN101575604B Slow virus vector, preparation thereof and application thereof
02/01/2011US7879993 Platelet derived growth factor (PDGF) nucleic acid ligand complexes
02/01/2011US7879989 Nucleotide sequences coding polypeptides for use in the diagnosis and treatment of cell proliferative disorders
02/01/2011US7879966 pH-sensitive polymer
02/01/2011US7879811 Formulations comprising antisense nucleotides to connexins
02/01/2011US7879810 That contain unmethylated cytosine-guanine (CpG) dinucleotides; stimulate an immune response and to redirect a Th2 response to a Th1 response; use with vaccines
02/01/2011US7879791 Regulation of T cell-mediated immunity by tryptophan
02/01/2011US7879609 Regulatory segments of the human gene for telomerase reverse transcriptase
02/01/2011US7879605 Methods and compositions for tissue regeneration
02/01/2011US7879602 Plasmid comprising toll-like receptor-3 (TLR-3) agonist promoter and influenza virus HA, influenza virus Ml, influenza virus NP and/or human immunodeficiency viral proteins; for use in eliciting antigen response in mammals
02/01/2011US7879588 Protein-proteophore complexes
02/01/2011US7879577 Modified polypeptides stabilized in a desired conformation and methods for producing same
02/01/2011US7879570 Nucleic acid and corresponding protein entitled 184P1E2 useful in treatment and detection of cancer
02/01/2011US7879340 blocking, reducing allergic rhinitis via antibodies contacting antigen, by administration of neurotoxin derived from Clostridium; absorbent pledgets, biodegradable carriers; lyophilization; liposomes
02/01/2011US7879334 Bifunctional fusion protein capable of binding to a immunoglobulin inhibitory receptor comprising an immune receptor tyrosine-based inhibitory motif (ITIM), expressed on mast cells, basophils or B cells for use in treatment of allergic disorders
02/01/2011US7879324 Using Fc epsilon R specific immunoglobulin fusion to treat and/or prevent type I hypersensitivity reaction
02/01/2011US7879323 Antibodies to fibroblast growth factor-like polypeptides
02/01/2011CA2547256C Adenovirus-transfected primary cells and methods of pathway mapping
02/01/2011CA2445260C Buffer solution for electroporation and a method comprising the use of the same
02/01/2011CA2380550C C type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
02/01/2011CA2359013C Compositions and methods for packaging of alphavirus vectors
02/01/2011CA2354508C Streptococcal c5a peptidase vaccine
02/01/2011CA2288943C Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
02/01/2011CA2282779C Formulation comprising an antigen, an adjuvant and an amino acid for use in immunization.
02/01/2011CA2222279C Hypoxia inducible factor-1 and method of use
01/2011
01/27/2011WO2011011700A2 Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
01/27/2011WO2011011631A2 Nucleic acid delivery vehicles
01/27/2011WO2011011061A2 Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy